Recent Finacing
Recent Raise
FORE Biotherapeutics develops plixorafenib, an oral dimer‑breaker BRAF inhibitor targeting V600, class‑2, fusions and splice variants, in clinical trials (including Phase 2 FORTE), using a functional genomics platform.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Fore Biotherapeutics.
